Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 10/20 | 1.00 |
| ▸ | JAK2 | O60674 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.52 |
| ▸ | ABL1 | P00519 | 2/20 | 0.50 |
| ▸ | BCR | P11274 | 2/20 | 0.50 |
| ▸ | AXL | P30530 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | CHUK | O15111 | 1/20 | 0.46 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549192 | 1.00 | PDPK1 (1.00) | PDPK1JAK2KDM4ECYP3A4GAA | |
| SCHEMBL786329 | 0.83 | JAK2 (1.00) | PDPK1JAK2KDM4ECYP3A4GAA | |
| Formic Acid Phenyl Ester SCHEMBL28129440 | 0.80 | PDPK1 (0.63) | PDPK1JAK2KDM4ECYP3A4GAA | |
| SCHEMBL922069 | 0.78 | PDPK1 (0.65) | PDPK1JAK2KDM4ECYP3A4GAA | |
| SCHEMBL31539770 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AAXLAURKB | |
| SCHEMBL11034 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AAXLAURKB | |
| SCHEMBL15288061 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AAXLAURKB | |
| SCHEMBL15288471 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AAXLAURKB | |
| SCHEMBL29490946 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AABL1AXL | |
| SCHEMBL2302544 | 0.78 | PDPK1 (0.63) | PDPK1JAK2DYRK1AAXLAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080001-A | Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof | — | 2026-05-26 | — | — | CN | claimed |
| CN-114573567-B | Indazole cyclotriazole compound and preparation method and application thereof | 西安交通大学 | 2023-05-02 | — | — | CN | claimed |
| CN-114573567-A | Indazole cyclic triazole compound and preparation method and application thereof | 西安交通大学 | 2022-06-03 | — | — | CN | claimed |
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | claimed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| CN-122080001-A | Perfluoroalkyl substituted pyrimido [1,2-b ] indazole ketone compound and preparation method thereof | — | 2026-05-26 | — | — | CN | disclosed |
| EP-3870583-B1 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-6610677-B2 | Enhancing glycogen synthesis, lowering blood levels of glucose, treating colon, ovarian, or breast cancer, treating diabetes, treating schizophrenia | VERTEX PHARMACEUTICALS INCORPORATED | 2003-08-26 | — | — | US | disclosed |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-01 | — | — | US | disclosed |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-24 | — | — | US | disclosed |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-17 | — | — | US | disclosed |
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-04-03 | — | — | US | disclosed |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064981-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3A | PDPK1 178/4885JAK2 456/4885KDM4E 975/4885 |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | PDPK1 4495/4885JAK2 1774/4885KDM4E 3563/4885 |
| US-20260021095-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | PSMB2, PSMB7, MDM2 | PDPK1 1180/4885JAK2 1686/4885KDM4E 1441/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | PDPK1 2427/4885JAK2 1297/4885KDM4E 1258/4885 |
| US-20030064982-A1 | Pyrazole compounds useful as protein kinase inhibitors | MAP3K20, CDK2, MAP2K2 | PDPK1 139/4885JAK2 352/4885KDM4E 596/4885 |
| US-20030083327-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDPK1 230/4885JAK2 690/4885KDM4E 921/4885 |
| US-20030055044-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDPK1 159/4885JAK2 487/4885KDM4E 605/4885 |
| US-20030073687-A1 | Pyrazole compounds useful as protein kinase inhibitors | AURKC, AURKA, GSK3B | PDPK1 239/4885JAK2 464/4885KDM4E 1142/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | PDPK1 3256/4885JAK2 640/4885KDM4E 2261/4885 |
| US-20030078166-A1 | Pyrazole compounds useful as protein kinase inhibitors | GSK3B, GSK3A, GSKIP | PDPK1 10/4885JAK2 553/4885KDM4E 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.